BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 30348944)

  • 1. Isolation of a novel glycyrrhizin metabolite as a causal candidate compound for pseudoaldosteronism.
    Morinaga O; Ishiuchi K; Ohkita T; Tian C; Hirasawa A; Mitamura M; Maki Y; Yasujima T; Yuasa H; Makino T
    Sci Rep; 2018 Oct; 8(1):15568. PubMed ID: 30348944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A semi-physiologically based pharmacokinetic pharmacodynamic model for glycyrrhizin-induced pseudoaldosteronism and prediction of the dose limit causing hypokalemia in a virtual elderly population.
    Xu R; Liu X; Yang J
    PLoS One; 2014; 9(12):e114049. PubMed ID: 25463381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adverse effects of licorice consumed as food: An update].
    Caré W; Grenet G; Schmitt C; Michel S; Langrand J; Le Roux G; Vodovar D
    Rev Med Interne; 2023 Sep; 44(9):487-494. PubMed ID: 37005098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study.
    Takahashi K; Yoshino T; Maki Y; Ishiuchi K; Namiki T; Ogawa-Ochiai K; Minamizawa K; Makino T; Nakamura T; Mimura M; Watanabe K
    Arch Toxicol; 2019 Nov; 93(11):3111-3119. PubMed ID: 31605160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Licorice: From Pseudohyperaldosteronism to Therapeutic Uses.
    Sabbadin C; Bordin L; Donà G; Manso J; Avruscio G; Armanini D
    Front Endocrinol (Lausanne); 2019; 10():484. PubMed ID: 31379750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18β-glycyrrhetyl-3-O-sulfate would be a causative agent of licorice-induced pseudoaldosteronism.
    Ishiuchi K; Morinaga O; Ohkita T; Tian C; Hirasawa A; Mitamura M; Maki Y; Kondo T; Yasujima T; Yuasa H; Minamizawa K; Namiki T; Makino T
    Sci Rep; 2019 Feb; 9(1):1587. PubMed ID: 30733510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
    Mitsumoto H; Cheung K; Oskarsson B; Andrews HF; Jang GE; Andrews JA; Shah JS; Fernandes JA; McElhiney M; Santella RM
    Trials; 2023 Jul; 24(1):449. PubMed ID: 37430314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of mesoderm introduction of compound glycyrrhizin injection on the treatment of rosacea.
    Li S; Zhao X; Chen Y; Liu J
    Skin Res Technol; 2023 May; 29(5):e13328. PubMed ID: 37231926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the network pharmacology and the structure-activity relationship of glycyrrhizic acid and glycyrrhetinic acid.
    Ni Q; Gao Y; Yang X; Zhang Q; Guo B; Han J; Chen S
    Front Pharmacol; 2022; 13():1001018. PubMed ID: 36313350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines.
    Li C; Jia WW; Yang JL; Cheng C; Olaleye OE
    Acta Pharmacol Sin; 2022 Dec; 43(12):3080-3095. PubMed ID: 36114271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Separation of Bioactive Natural Compounds from Crude Drug Extract and Its Application for Cell-Based Studies.
    Uto T; Ohta T; Fujii S; Shoyama Y
    Antibodies (Basel); 2021 Dec; 10(4):. PubMed ID: 34940000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Risk Factors of Licorice-Induced Pseudoaldosteronism Based on Glycyrrhizin-Metabolite Concentrations: A Narrative Review.
    Yoshino T; Shimada S; Homma M; Makino T; Mimura M; Watanabe K
    Front Nutr; 2021; 8():719197. PubMed ID: 34604277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an Alternative Glycyrrhizin Metabolite Causing Liquorice-Induced Pseudohyperaldosteronism and the Development of ELISA System to Detect the Predictive Biomarker.
    Ishiuchi K; Morinaga O; Yoshino T; Mitamura M; Hirasawa A; Maki Y; Tashita Y; Kondo T; Ogawa K; Lian F; Ogawa-Ochiai K; Minamizawa K; Namiki T; Mimura M; Watanabe K; Makino T
    Front Pharmacol; 2021; 12():688508. PubMed ID: 34079468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule.
    Lan XF; Olaleye OE; Lu JL; Yang W; Du FF; Yang JL; Cheng C; Shi YH; Wang FQ; Zeng XS; Tian NN; Liao PW; Yu X; Xu F; Li YF; Wang HT; Zhang NX; Jia WW; Li C
    Acta Pharmacol Sin; 2021 Dec; 42(12):2155-2172. PubMed ID: 33931765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration for the real causative agents of licorice-induced pseudoaldosteronism.
    Makino T
    J Nat Med; 2021 Mar; 75(2):275-283. PubMed ID: 33481180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
    Bailly C; Vergoten G
    Pharmacol Ther; 2020 Oct; 214():107618. PubMed ID: 32592716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Compound Glycyrrhizin Capsules Combined with a Topical Corticosteroid in Adults with Chronic Eczema.
    Xu W; Li Y; Ju M; Lai W; Lu X; Shi H; Shi W; Gu H; Li L
    Evid Based Complement Alternat Med; 2020; 2020():6127327. PubMed ID: 32308712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of calcium-induced differentiation potential and tight junction formation in HaCaT keratinocytes by functional attenuation of overexpressed high mobility group box-1 protein.
    Tanaka F; Uda M; Hirose Y; Hirai Y
    Cytotechnology; 2020 Feb; 72(1):165-174. PubMed ID: 31916113
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.